Peter L. Hoang
CIK 1626893 · President and CEO · last filed 2022-03-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$733.7K
Companies
3
Total Filings
11
Lifetime Open-Market Net
$296.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MRKR | President and CEO | 531,662 | $1.38 | $733.7K | $296.2K | 7 | 2022-03-28 |
| Marker Therapeutics, Inc. (TPIV) Delisted | CEO and President | 179,711 | — | — | $0 | 1 | 2017-09-25 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Sr. VP of Bus. Development | — | $0.07 | — | $0 | 3 | 2017-01-05 |
Recent Filings · Page 2 of 2
11 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-02-26 | BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 11–11 of 11
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.